Vaxcyte, Inc. (MUN:5VA)

Market Cap	5.44B
Revenue (ttm)	n/a
Net Income (ttm)	-560.13M
Shares Out	n/a
EPS (ttm)	-4.13
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	130
Open	41.60
Previous Close	39.20
Day's Range	41.60 - 41.60
52-Week Range	25.80 - 63.50
Beta	n/a
RSI	42.39
Earnings Date	Feb 25, 2026

About Vaxcyte

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused b...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2013
• Employees: 414
• Stock Exchange: Munich Stock Exchange
• Ticker Symbol: 5VA

Financial Performance

Financial numbers in USD